BioXcel Historical Income Statement
| BTAI Stock | USD 2.16 0.43 24.86% |
Historical analysis of BioXcel Therapeutics income statement accounts such as Selling General Administrative of 76.7 M, Total Revenue of 1.7 M or Gross Profit of 144.9 K can show how well BioXcel Therapeutics performed in making a profits. Evaluating BioXcel Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of BioXcel Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining BioXcel Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioXcel Therapeutics is a good buy for the upcoming year.
BioXcel |
About BioXcel Income Statement Analysis
BioXcel Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to BioXcel Therapeutics shareholders. The income statement also shows BioXcel investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
BioXcel Therapeutics Income Statement Chart
Add Fundamental
Net Income Applicable To Common Shares
The net income that remains after preferred dividends have been deducted, available to common shareholders.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of BioXcel Therapeutics. It is also known as BioXcel Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from BioXcel Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into BioXcel Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.As of now, BioXcel Therapeutics' Gross Profit is increasing as compared to previous years. The BioXcel Therapeutics' current Other Operating Expenses is estimated to increase to about 209.1 M, while Operating Income is forecasted to increase to (146.9 M).
BioXcel Therapeutics income statement Correlations
Click cells to compare fundamentals
BioXcel Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioXcel Therapeutics income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 27K | 40K | 8.2M | 13.3M | 15.3M | 16.1M | |
| Selling General Administrative | 24.3M | 54.2M | 68.8M | 63.5M | 73.0M | 76.7M | |
| Operating Income | (82.3M) | (106.9M) | (159.6M) | (171.8M) | (154.6M) | (146.9M) | |
| Income Before Tax | (82.2M) | (106.9M) | (165.8M) | (179.1M) | (161.1M) | (153.1M) | |
| Net Income Applicable To Common Shares | (33.0M) | (82.2M) | (106.9M) | (165.8M) | (149.2M) | (141.7M) | |
| Net Income | (82.0M) | (106.6M) | (171.8M) | (179.1M) | (161.1M) | (153.1M) | |
| Gross Profit | 24.3 | (297K) | 355K | 120K | 138K | 144.9K | |
| Other Operating Expenses | 82.3M | 106.9M | 160.0M | 173.2M | 199.1M | 209.1M | |
| Net Income From Continuing Ops | (82.3M) | (106.9M) | (165.8M) | (211.6M) | (190.4M) | (180.9M) | |
| Ebit | (82.3M) | (106.9M) | (157.7M) | (165.7M) | (149.2M) | (141.7M) | |
| Research Development | 58.0M | 52.7M | 91.2M | 84.3M | 97.0M | 101.8M | |
| Ebitda | (82.1M) | (106.6M) | (157.4M) | (165.4M) | (148.9M) | (141.4M) | |
| Cost Of Revenue | 188K | 297K | 20K | 1.3M | 1.4M | 1.5M | |
| Total Operating Expenses | 82.3M | 106.9M | 160M | 171.9M | 197.7M | 207.6M | |
| Total Other Income Expense Net | 128K | 4K | (6.1M) | (7.3M) | (6.5M) | (6.2M) | |
| Income Tax Expense | (161K) | (301K) | 6.1M | 150.1K | 172.6K | 164.0K | |
| Interest Income | 155K | 44K | 2.5M | 6.2M | 7.1M | 7.5M | |
| Depreciation And Amortization | 188K | 297K | 327K | 318K | 365.7K | 384.0K | |
| Reconciled Depreciation | 188K | 297K | 327K | 321K | 369.2K | 205.4K |
Currently Active Assets on Macroaxis
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (32.64) | Revenue Per Share | Quarterly Revenue Growth (0.37) | Return On Assets | Return On Equity |
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.